4-[2-[2-[4-[(4-Chlorophenyl)methylsulfanyl]phenoxy]butanoyl]-4-methyl-1,3-thiazol-5-yl]butanoic acid | 273939-21-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 4-[2-[2-[4-[(4-Chlorophenyl)methylsulfanyl]phenoxy]butanoyl]-4-methyl-1,3-thiazol-5-yl]butanoic acid
• CAS: 273939-21-2
• 化学式: C₂₅H₂₆ClNO₄S₂
• 分子量: 504.071
• InChiKey: VXBKKULJASNLIC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  33
• 可旋转键数：
  12
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  130
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  4-(4-chloro-benzylsulfanyl)-phenol 在 caesium carbonate 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 生成 4-[2-[2-[4-[(4-Chlorophenyl)methylsulfanyl]phenoxy]butanoyl]-4-methyl-1,3-thiazol-5-yl]butanoic acid
  参考文献：
  名称：

  Design of novel and potent cPLA2α inhibitors containing an α-methyl-2-ketothiazole as a metabolically stable serine trap

  摘要：

  We report the design of novel, potent cPLA(2)alpha inhibitors that possess an alpha-methyl-2-ketothiazole that acts as a serine-reactive moiety. We describe the optimization of the series for potency and metabolic stability towards ketone reduction. This was achieved by attenuating the reactivity of the ketone using a combination of electronic and steric effects. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.03.005

文献信息

• NOVEL COMPOUNDS
  申请人：AstraZeneca AB

  公开号：EP1135377A1

  公开（公告）日：2001-09-26
• [EN] NOVEL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSES
  申请人：ASTRAZENECA UK LTD

  公开号：WO2000034254A1

  公开（公告）日：2000-06-15

  Compounds of formula (I) are disclosed, processes for their preparation, pharmaceutical compositions containing the compounds and the use of the compounds as pharmaceuticals. There are also provided chemical intermediates useful for the preparation of the compounds. The compounds are useful as pharmaceuticals, especially for the treatment of inflammatory disease.
• Design of novel and potent cPLA2α inhibitors containing an α-methyl-2-ketothiazole as a metabolically stable serine trap
  作者：Antonio Mete、Glen Andrews、Mike Bernstein、Stephen Connolly、Paul Hartopp、Clive G. Jackson、Richard Lewis、Iain Martin、David Murray、Rob Riley、David H. Robinson、Gill M. Smith、Edward Wells、W. John Withnall

  DOI：10.1016/j.bmcl.2011.03.005

  日期：2011.5

  We report the design of novel, potent cPLA(2)alpha inhibitors that possess an alpha-methyl-2-ketothiazole that acts as a serine-reactive moiety. We describe the optimization of the series for potency and metabolic stability towards ketone reduction. This was achieved by attenuating the reactivity of the ketone using a combination of electronic and steric effects. (C) 2011 Elsevier Ltd. All rights reserved.